We re-do all clinical studies, says GVK Bio – Business Standard News

0

The company had taken a Rs 60-crore hit as new orders from the clients were stopped from August

Hyderabad-based contract research organisation GVK Biosciences on Monday said the company was ready to re-do all the clinical studies of drugs over which the European Medicines Agency (EMA) raised an alarm citing the findings of French drug regulatory agency, ANSM.

Read more – Business Standard News

 

share >>>
December 8, 2014 |

Leave a Reply

Vantage Theme – Powered by WordPress.
Skip to toolbar